MedImmune

incomplete railroad tracks in namibia
Biotech

Kiniksa adds to Sjögren's exodus, axes AstraZeneca asset

Kiniksa is stopping a midphase autoimmune trial and returning a candidate to AstraZeneca as it doubles down on its cardiovascular pipeline.
Nick Paul Taylor Feb 25, 2025 10:09am
beach sand footprints water ocean footsteps

Moderna culls 4 clinical assets

Sep 13, 2023 5:58pm
Deal terminate tear up end deal scrap

AstraZeneca pulls pneumonia collab with Aridis, halting phase 3

Mar 29, 2023 10:45am
visual rendering of an antibody drug conjugate

Pheon hauls in $68M series A off the excitement of budding ADCs

Sep 28, 2022 3:00am